Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.

Melero I, Yau T, Kang YK, Kim TY, Santoro A, Sangro B, Kudo M, Hou MM, Matilla A, Tovoli F, Knox J, He AR, El-Rayes B, Acosta-Rivera M, Lim HY, Soleymani S, Yao J, Neely J, Tschaika M, Hsu C, El-Khoueiry AB.

Open source

DOI
10.1016/j.annonc.2024.03.005
Published
2024-05-22
Container
Ann Oncol
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2024.03.005,
  title = {Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.},
  author = {Melero I and  Yau T and  Kang YK and  Kim TY and  Santoro A and  Sangro B and  Kudo M and  Hou MM and  Matilla A and  Tovoli F and  Knox J and  He AR and  El-Rayes B and  Acosta-Rivera M and  Lim HY and  Soleymani S and  Yao J and  Neely J and  Tschaika M and  Hsu C and  El-Khoueiry AB.},
  year = {2024},
  journal = {Ann Oncol},
  doi = {10.1016/j.annonc.2024.03.005},
  url = {https://doi.org/10.1016/j.annonc.2024.03.005}
}

RIS

TY  - JOUR
TI  - Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
AU  - Melero I
AU  -  Yau T
AU  -  Kang YK
AU  -  Kim TY
AU  -  Santoro A
AU  -  Sangro B
AU  -  Kudo M
AU  -  Hou MM
AU  -  Matilla A
AU  -  Tovoli F
AU  -  Knox J
AU  -  He AR
AU  -  El-Rayes B
AU  -  Acosta-Rivera M
AU  -  Lim HY
AU  -  Soleymani S
AU  -  Yao J
AU  -  Neely J
AU  -  Tschaika M
AU  -  Hsu C
AU  -  El-Khoueiry AB.
PY  - 2024
JO  - Ann Oncol
DO  - 10.1016/j.annonc.2024.03.005
UR  - https://doi.org/10.1016/j.annonc.2024.03.005
ER  - 

APA

I, M., T, Y., YK, K., TY, K., A, S., B, S., M, K., MM, H., A, M., F, T., J, K., AR, H., B, E., M, A., HY, L., S, S., J, Y., J, N., M, T., C, H., & AB., E. (2024). Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.. Ann Oncol. https://doi.org/10.1016/j.annonc.2024.03.005

Source records